Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Brown-Forman Class B
BF.B
$12.9B
| $21.8M | 0.03% |
+700,234
| New | +$22M |
|
802
Coca-Cola Europacific Partners
CCEP
$47.5B
| $21.8M | 0.03% |
534,938
-278,126
| -34% | -$11M |
|
|
ANAT
803
DELISTED
American National Group, Inc. Common Stock
ANAT
| $21.7M | 0.03% |
186,700
+8,700
| +5% | +$1.01M |
|
|
EGOV
804
DELISTED
NIC Inc
EGOV
| $21.7M | 0.03% |
1,144,858
+29,898
| +3% | +$611K |
|
805
Bright Horizons
BFAM
$3.85B
| $21.7M | 0.03% |
280,700
+183,200
| +188% | +$13.9M |
|
|
SGBK
806
DELISTED
Stonegate Bank
SGBK
| $21.6M | 0.03% |
468,522
+151,522
| +48% | +$6.95M |
|
807
Morgan Stanley
MS
$343B
| $21.6M | 0.03% |
+484,000
| New | +$20.9M |
|
808
SunCoke Energy
SXC
$788M
| $21.5M | 0.03% |
1,972,800
-630,800
| -24% | -$5.77M |
|
|
GG
809
DELISTED
Goldcorp Inc
GG
| $21.4M | 0.03% |
+1,661,499
| New | +$23.3M |
|
810
Mercantile Bank Corp
MBWM
$1.06B
| $21.4M | 0.03% |
681,215
+12,300
| +2% | +$402K |
|
|
SHOR
811
DELISTED
ShoreTel, Inc.
SHOR
| $21.4M | 0.03% |
3,694,584
+221,900
| +6% | +$1.36M |
|
|
BRKL
812
DELISTED
Brookline Bancorp
BRKL
| $21.4M | 0.03% |
1,467,700
+210,900
| +17% | +$3.06M |
|
813
Ferrari
RACE
$72.5B
| $21.3M | 0.03% |
248,175
-139,747
| -36% | -$11.4M |
|
814
Seaboard Corp
SEB
$4.08B
| $21.3M | 0.03% |
5,322
+416
| +8% | +$1.67M |
|
815
MPLX
MPLX
$59.6B
| $21.3M | 0.03% |
636,467
-467,500
| -42% | -$16.2M |
|
816
SS&C Technologies
SSNC
$19.3B
| $21.2M | 0.03% |
552,600
+77,500
| +16% | +$2.89M |
|
|
QADA
817
DELISTED
QAD Inc.
QADA
| $21.2M | 0.03% |
661,177
+62,300
| +10% | +$1.91M |
|
|
PTLA
818
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $21.2M | 0.03% |
+377,200
| New | +$15.1M |
|
819
Orthofix Medical
OFIX
$415M
| $21.2M | 0.03% |
455,579
-285,000
| -38% | -$11.8M |
|
|
LGTY
820
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $21.1M | 0.03% |
2,050,700
+92,500
| +5% | +$1M |
|
821
Valley National Bancorp
VLY
$8.3B
| $21.1M | 0.03% |
1,784,158
-1,071,530
| -38% | -$12.5M |
|
|
GHL
822
DELISTED
Greenhill & Co., Inc.
GHL
| $21M | 0.03% |
1,047,000
+224,400
| +27% | +$5.25M |
|
|
CHU
823
DELISTED
China Unicom (HONG KONG) Limited
CHU
| $21M | 0.03% |
1,400,800
-143,500
| -9% | -$2M |
|
|
ZNH
824
DELISTED
China Southern Airlines Company Limited
ZNH
| $20.9M | 0.03% |
505,800
+11,900
| +2% | +$440K |
|
825
Middlesex Water
MSEX
$1.11B
| $20.9M | 0.03% |
528,400
+32,400
| +7% | +$1.21M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.